Search

Author/Creator McCleod, M

1. LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (23rd October 2018)

Authors:
Cappuzzo, F; McCleod, M; Hussein, M; Morabito, A; Rittmeyer, A; Conter, H J; Kopp, H-G; Daniel, D; McCune, S; Mekhail, T; Zer, A; Reinmuth, N; Sadiq, A; Archer, V; Ochi Lohmann, T; Wang, L; Kowanetz, M; Lin, W; Sandler, A; West, H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. LBA64nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. (23rd October 2018)

Authors:
Spigel, D R; Jotte, R M; Ponce Aix, S; Gressot, L; Morgensztern, D; McCleod, M; Socinski, M A; Daniel, D; Juan-Vidal, O; Kim, E S; West, H J; Chen, T; Bhore, R; Ong, T J; Gridelli, C; Thomas, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LBA65IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. (23rd October 2018)

Authors:
Socinski, M A; Rittmeyer, A; Shapovalov, D; Orlandi, F; McCleod, M; Soo, R A; Palmero, R; Kozuki, T; Migliorino, M R; Koynov, K D; Berard, H; Hughes, B G M; Yu, W; Graupner, V; Sun, S W; Kowanetz, M; Hoang, T; Lin, W; Jotte, R M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search